Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3

  • Bioorg Med Chem Lett. 2006 Nov 1;16(21):5633-8. doi: 10.1016/j.bmcl.2006.08.022.
Jack J Chen  1 ,  Kumar D Thakur ,  Michael P Clark ,  Steven K Laughlin ,  Kelly M George ,  Roger G Bookland ,  Jan R Davis ,  Edward J Cabrera ,  Vijay Easwaran ,  Biswanath De ,  Y George Zhang
Affiliations
  • 1. Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA. [email protected]
PMID: 16934457 DOI: 10.1016/j.bmcl.2006.08.022
Abstract

A new class of pyrimidine-based Janus tyrosine kinase 3 (JAK3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK3.

Products